The ABCF2 antibody targets the ATP-binding cassette subfamily F member 2 (ABCF2), a protein belonging to the ABC transporter superfamily. ABCF2 is distinct from other ABC proteins as it lacks transmembrane domains, suggesting non-canonical roles unrelated to substrate transport. It is ubiquitously expressed in human tissues and primarily localized in the cytoplasm or endoplasmic reticulum. Research indicates ABCF2 involvement in cellular processes such as ribosome biogenesis, translation regulation, and apoptosis. Studies have linked its overexpression to cancer progression, including ovarian, lung, and hepatocellular carcinomas, where it may promote chemoresistance by modulating drug efflux or survival pathways. Conversely, reduced ABCF2 levels correlate with neurodegenerative disorders like Parkinson’s disease, implying a neuroprotective function. The ABCF2 antibody is widely used in research to detect protein expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. It aids in elucidating ABCF2’s molecular interactions, particularly its ATPase activity and association with translation machinery. Commercially available antibodies are typically validated for specificity using knockout cell lines or siRNA knockdown. Ongoing studies explore its potential as a diagnostic biomarker or therapeutic target, though functional mechanisms remain partially unresolved.